Just over $20M PAR/FocalinXR sales during IPCI's fiscal Q2...and just over $17M PAR/FocalinXR sales during IPCI's fiscal Q3...yet IPCI's actual reported revenues came nowhere close to matching those reported Q3 PAR/FocalinXR sales numbers from Bloomberg...meaning the Bloomberg numbers were wrong...or IPCI just had their PAR/FocalinXR profit sharing licensing deal terms changed to a drastically reduced level after their fiscal Q2 earnings without informing anyone lol.
Market Data 
Markets 
AI
